Neil Kumar

CEO Neil Kumar sells 80,000 BBIO shares for $5.4M under pre-arranged 10b5-1 plan on 2026-06-04/05

Neil Kumar, Chief Executive Officer of BridgeBio Pharma, executed 14 separate sales totaling 80,000 shares for $5,413,288.79 at a blended average price of $67.67 across June 4–5, 2026. This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-03-31, meaning the sales were scheduled in advance and not discretionary decisions. Kumar retains 4,318,447 shares post-transaction, representing a -1.8% reduction in his holdings. The company is unprofitable with net income of $-166,555,000.00 on quarterly revenue of $194,515,000.00, though annual revenue growth stands at +126.3%. The stock currently trades at $67.37, -20.7% from its 52-week high of $84.94 and -9.4% over the past 90 days, placing the transaction near recent lows within the year's range.

CEO Neil Kumar sold 26,103 shares for $1.8M (blended avg $69.44) on 2026-05-21 under pre-arranged 10b5-1 plan.

CEO Neil Kumar executed five separate sales totaling 26,103 shares for $1,812,521.76 on a single trading date, reducing his holdings by 9.7% to 243,327 shares. This transaction was scheduled under a pre-arranged 10b5-1 trading plan adopted on 2025-03-31, meaning it was not a discretionary decision but part of a predetermined execution schedule. The stock currently trades at $67.73, down 20.3% from its 52-week high of $84.94 and off 7.6% over the past 30 days, though it has gained 1.8% over 90 days. BridgeBio remains unprofitable with a $-166.6M net loss in the most recent quarter against $194.5M in revenue, though the company has achieved 126.3% annual revenue growth. Since this sale was scheduled rather than discretionary, it does not signal conviction or concern about near-term valuation; investors should focus instead on the company's fundamental trajectory as a high-growth but currently loss-making pharma organization.

BridgeBio CEO Kumar Neil sells ~$5.4M of stock (80,000 shares) via 12 transactions; his 126th-137th open-market sale in 3 years, no purchases.

Kumar Neil, BridgeBio's CEO, sold approximately 80,000 shares over two trading days in early May totaling roughly $5.4M—his 126th through 137th open-market sale in the past three years, with zero open-market purchases in that period. The stock currently trades roughly 15% below its 52-week high and has declined modestly over the past three months, creating a backdrop where the CEO is choosing to reduce his position. His five prior sales at BridgeBio were all followed by stock declines, demonstrating consistent timing accuracy on those exits. The company is unprofitable on an annual basis, though quarterly results show a modest loss, alongside strong revenue growth that has more than doubled year-over-year, suggesting a cash-intensive growth business. The sale itself is not unusual for a pharmaceutical company burning cash, but the three-year pattern of continuous selling and complete absence of any open-market purchases is noteworthy for someone running the company—it reflects a persistent divestiture posture rather than conviction in the business or willingness to put personal capital at risk.

CEO Kumar Neil sold 80,000 shares of BBIO for $5,968,780.09 via scheduled 10b5-1 plan on 2026-04-09–10

Kumar Neil, CEO of BridgeBio Pharma, executed 8 separate sales totaling 80,000 shares for $5,968,780.09 at prices ranging from $73.64 to $75.55, reducing his holdings from 4,478,447 shares to 4,398,447 shares (-1.8%). This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-03-31, meaning the sales were scheduled and not discretionary in timing or execution. The CEO retains substantial post-transaction holdings of 4,398,447 shares, indicating continued material ownership alignment with the company. As a scheduled plan, this sale carries no implications about the insider's current conviction or market outlook.

BridgeBio CEO Kumar Neil sells 80,000 shares for $5.5M via scheduled 10b5-1 plan on 2026-03-12 to 2026-03-13

Kumar Neil, Chief Executive Officer of BridgeBio Pharma, executed 10 separate sales totaling 80,000 shares for $5,501,068.07 across two trading dates (2026-03-12 and 2026-03-13), with transactions priced between $68.36 and $70.15 per share and a blended average price of $68.76. This sale represents a 1.8% reduction in his post-transaction holdings of 4,438,447 shares, bringing his total shareholding from 4,518,447 shares. The transaction was executed pursuant to a pre-arranged 10b5-1 trading plan adopted on 2025-03-31, indicating the timing and volume were determined in advance and do not reflect discretionary decision-making. As a scheduled divestiture under a pre-existing plan, this sale provides limited direct signals about near-term company fundamentals or the CEO's current confidence posture.

CEO Kumar Neil sold 28,053 shares for $2,002,717.48 under pre-arranged 10b5-1 plan on 2026-02-19

Kumar Neil, Chief Executive Officer of BridgeBio Pharma, executed 3 separate sales totaling 28,053 shares for $2,002,717.48 on 2026-02-19 at prices ranging from $71.03 to $72.80, reducing his holdings by 10.7% from 262,504 to 234,451 shares. This transaction was conducted under a pre-arranged 10b5-1 trading plan adopted on 2025-03-31, meaning it was scheduled rather than discretionary. The systematic nature of the plan limits inference about timing or market sentiment, as the trades followed a predetermined schedule established nearly 11 months prior. Investors should note the transaction's mechanical character while monitoring whether the CEO's post-transaction holdings level signals any strategic positioning change.

CEO Kumar Neil sold 80,000 shares of BBIO for $5,748,666.24 via 10b5-1 plan

CEO Kumar Neil executed 12 separate sales totaling 80,000 shares for $5,748,666.24 on 2026-02-10 and 2026-02-11, reducing his holdings from 4,558,447 shares to 4,478,447 shares. These transactions are governed by a pre-arranged 10b5-1 trading plan adopted on 2025-03-31, meaning the sales were scheduled rather than discretionary. The blended average price across all transactions was $71.86, with individual sale prices ranging from $70.69 to $73.25 across the two-day window. Post-transaction, the CEO retains substantial equity holdings of 4,478,447 shares in BridgeBio Pharma.

CEO Kumar Neil sells 80,000 BBIO shares for $6.0M over two days; retains 4.52M shares post-sale.

Kumar Neil, Chief Executive Officer of BridgeBio Pharma, executed 14 separate sales totaling 80,000 shares for $6,043,168.21 across January 8–9, 2026, at an average price of $75.54. This represents a 1.7% reduction from pre-transaction holdings of 4.60M shares, leaving him with 4.52M shares—a substantial continued position. The company is unprofitable with net income of $-184,937,000.00 over its most recent full fiscal year, though it has experienced explosive annual revenue growth of +2285.3%. The sale occurred when the stock was near its 52-week high of $78.24 (current price $76.84 is -1.8% from that high), and the stock has delivered a strong 90-day return of +36.0% heading into this transaction. Against the backdrop of a loss-making but rapidly scaling revenue base, a large-dollar insider sale by the CEO at elevated valuation levels merits attention to understand the commercial context and capital allocation priorities.

CEO Kumar Neil sold 30,011 shares (30.0K) for $2,239,902.15 under pre-arranged 10b5-1 plan

CEO Kumar Neil executed 2 separate sales totaling 30,011 shares on 2025-12-15 at blended average price of $74.64, reducing his holdings from 258,787 shares to 228,776 shares (-11.6% reduction). This transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2025-03-31, meaning it was scheduled in advance and not a discretionary decision. Because the sales were scheduled under a 10b5-1 plan, they do not reflect current market judgment or conviction but rather an automated execution of a plan established months prior. Investors should note that while the transaction is material in absolute dollar terms ($2.2M), the systematic nature of 10b5-1 sales limits their interpretive value as a signal of insider intent.

BridgeBio Pharma CEO Kumar Neil sells 80,000 shares for $5.9M under pre-arranged 10b5-1 plan

Kumar Neil, Chief Executive Officer of BridgeBio Pharma (BBIO), executed 10 separate sales totaling 80,000 shares for $5,908,475.90 across December 4-5, 2025, at a blended average price of $73.86. The sales reduced his holdings from 4,638,447 shares to 4,558,447 shares, a decrease of 1.7%. This activity is part of a pre-arranged 10b5-1 trading plan adopted on 2025-03-31, meaning the transactions were scheduled and not discretionary decisions made in response to current market or company conditions. While the CEO retains substantial holdings of 4.56M shares post-transaction, the scheduled nature of the plan limits inference about his current sentiment toward the company.